Sr. Vice President, U.S. Neurology and Rare
Mike Davis is head of U.S. Neurology & Rare at UCB, where his goal is to make the lives of patients better every day. By focusing on science and on patient care, and embracing the role of digital and innovation, Mike believes we can evolve our business models to make the most impact for people living with severe diseases and for UCB.
Mike is skilled in building organizations with the vision and grit to tackle a continuous evolution of health care challenges by translating those strategies into real-world value. As head of U.S. Neurology & Rare, he oversees a team responsible for a portfolio of epilepsy and Parkinson’s products, which have impacted the lives of nearly 500,000 patients. As UCB evolves our presence into Rare Disease, Mike’s team will continue to build on our proximity to patients and legitimacy within neurology to demonstrate that UCB is driven by patient value, not by patient numbers.
Mike also serves on the U.S. Leadership Team, where he is an advocate for UCB’s Diversity, Equity, and Inclusion efforts and serves as the Executive Sponsor of UCB’s Women in Leadership (WiL) organization. He is also the Global Commercial Lead and Executive Sponsor for UCB’s Digital Business Transformation, which seeks to amplify the power of scientific innovation to create sustainable value for patients. In 2020, the U.S. team won a Reuters Events Award for a digital transformation initiative by engaging physicians through data and insights to better meet patient needs.
As part of his leadership, Mike serves as the champion for an Integrated Go-to-Market (iG2M) operating model, which aims to bring UCB’s internal teams and the external ecosystems closer to patients in the systems in which they receive care. This business approach ensures consistency and synergies across teams, and, in 2019, UCB won an EyeForPharma Award award for their agile transformation.
Before his role as head of U.S. Neurology, Mike was a key force behind the creation of UCB’s Seizure Freedom Mission, and was responsible for the strategic and organizational structure that brought together patient insights, the new R&D paradigm, technology, innovation partnerships, and built on UCB’s leadership as a developer of anti-epileptic medicines to pioneer transformative new approaches to the care of people with seizure disorders. He served as vice president for the patient solutions team in the Asia Pacific region (APAC), based in Shanghai, China, where he delivered significant growth goals across multiple and complex geographies while redesigning UCB’s approach in the region to match their ambition as a biopharma leader.
Mike first joined UCB as part of the Schwarz Pharma acquisition, following which he headed up the launch team for Neupro® in the U.S., and eventually moved to Global CNS marketing group director in Belgium where he was responsible for re-establishing the Neupro brand and accelerating growth across the EU.
Prior to joining Schwarz Pharma, Mike spent a decade at Forest Laboratories where he was directly involved in several launches, including three of the company’s most successful products in depression and Alzheimer’s.
In his early career, Mike worked in basic science as a bench scientist in both clinical and commercial-based labs. He has a Bachelor of Science degree from Sienna College and an MBA from Adelphi University.
Currently, Mike serves as a Board Member for both U-PAC and Engage Therapeutics and lives outside Atlanta, Georgia, with his wife, Maureen, and their two sons.